Johnny Nagasawa

Discovery and SAR of 5-(3-Chlorophenylamino)benzo[<i>c</i>][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer

Fabrice Pierre, Peter Chua, Sean O’Brien et al. · Journal of Medicinal Chemistry · 2010 · 299 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts

Andiliy Lai, Mehmet Kahraman, Steven P. Govek et al. · Journal of Medicinal Chemistry · 2015 · 247 citations · Full text

Medicine, Oncology, Pharmacology +13

Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics

Mustapha Haddach, Michael K. Schwaebe, Jerome Michaux et al. · ACS Medicinal Chemistry Letters · 2012 · 164 citations

Life Sciences, Oncology, Pharmacology +14

Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer

Fabrice Pierre, Peter Chua, Sean O’Brien et al. · Molecular and Cellular Biochemistry · 2011 · 155 citations

Medicine, Medicinal Chemistry, Pharmacology +4

The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer

James D. Joseph, Beatrice Darimont, Wei Zhou et al. · eLife · 2016 · 119 citations · Full text

Medicine, Oncology, Pharmacology +15